ALIGOS Aktie

 

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on December 9, 2025 (the “Grant Date”), in connection with the commencement of employment....

Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 23,600 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on November 11, 2025 (the “Grant Date”), in connection with the commencement of employment....

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025....

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences....

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets....

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 27,400 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on October 15, 2025 (the “Grant Date”), in connection with the commencement of employment....

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection....

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright Liver Disease Conference being held October 21 - 22, 2025....

Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184...

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany....

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025....

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately....

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment....

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025....

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets....